RAPT Therapeutics, Inc. clinical trials
Acquired by GlaxoSmithKline, Mar 3, 2026 · source ↗
The registry lists 8 studies whose lead sponsor is RAPT Therapeutics, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2026.
- 8studies on the registry
- 0open to participants now
- 1reach primary completion within a year
Before and after it joined GlaxoSmithKline
- First submitted before RAPT Therapeutics, Inc. became part of GlaxoSmithKline
- 8
- First submitted after RAPT Therapeutics, Inc. became part of GlaxoSmithKline
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs RAPT Therapeutics, Inc.’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
Coming up
1 of RAPT Therapeutics, Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- 1MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 8 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 223
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- RAPT Therapeutics, Inc.7 studies
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies1 study
Something wrong with this grouping? Tell us on the GlaxoSmithKline page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All GlaxoSmithKline studies →
- Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food AllergyActive, not recruitingNCT07220811Phase 2
Sponsor listed in the registry: RAPT Therapeutics, Inc., a member of the GSK plc group of companies · First submitted before RAPT Therapeutics, Inc. became part of GlaxoSmithKline
- Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedNCT03674567Phase 1/2
Sponsor listed in the registry: RAPT Therapeutics, Inc. · First submitted before RAPT Therapeutics, Inc. became part of GlaxoSmithKline
- An Efficacy and Safety Study of RPT193 in Adults With Atopic DermatitisTerminatedNCT05399368Phase 2
Sponsor listed in the registry: RAPT Therapeutics, Inc. · First submitted before RAPT Therapeutics, Inc. became part of GlaxoSmithKline
- Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high AsthmaTerminatedNCT05935332Phase 2
Sponsor listed in the registry: RAPT Therapeutics, Inc. · First submitted before RAPT Therapeutics, Inc. became part of GlaxoSmithKline
- FLX475 in Combination With Ipilimumab in Advanced MelanomaTerminatedNCT04894994Phase 2
Sponsor listed in the registry: RAPT Therapeutics, Inc. · First submitted before RAPT Therapeutics, Inc. became part of GlaxoSmithKline
- Study of RPT193 in Healthy Adult Male SubjectsCompletedNCT06087978Phase 1
Sponsor listed in the registry: RAPT Therapeutics, Inc. · First submitted before RAPT Therapeutics, Inc. became part of GlaxoSmithKline
- A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic DermatitisCompletedNCT04271514Phase 1
Sponsor listed in the registry: RAPT Therapeutics, Inc. · First submitted before RAPT Therapeutics, Inc. became part of GlaxoSmithKline
- First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02335814Phase 1
Sponsor listed in the registry: RAPT Therapeutics, Inc. · First submitted before RAPT Therapeutics, Inc. became part of GlaxoSmithKline